PURPOSE: Plasmalemmal vesicle associated protein-1 (PV-1) is up-regulated in the endothelium of human glioblastoma. We sought to further characterize the expression pattern of PV-1 in human brain tumors and interrogate its role in brain tumor angiogenesis. EXPERIMENTAL DESIGN: Quantitative reverse transcription-PCR and in situ hybridization were used to measure PV-1 expression in a panel of 46 human brain tumors and related pathologic states. Matrigel tubulogenesis assays and cell migration assays were used to show function of PV-1 in primary human endothelial cells (HMVEC) under gene knockdown conditions. RESULTS: PV-1 is selectively up-regulated in a variety of high-grade human brain tumors, including glioblastoma and metastatic carcinoma, as well as other cerebral disorders associated with blood-brain barrier disruption, such as acute ischemia. Expression levels were reduced in low-grade neoplasia; however, tumors associated with the ependyma and choroid plexus, known sites of PV-1 expression, also exhibited robust expression. Cerebral expression of PV-1 mRNA was confined to endothelial cells in all cases. PV-1 expression was induced in HMVEC cells in vitro by exposure to medium conditioned by U87MG and U251MG human brain tumor cell lines and by medium supplemented with exogenous vascular endothelial growth factor or scatter factor/hepatocyte growth factor. RNA interference-mediated inhibition of PV-1 induction in HMVEC cells blocked Matrigel-induced tubulogenesis and inhibited cell migration induced by conditioned medium or angiogenic growth factors. CONCLUSIONS: Our results confirm that PV-1 is preferentially induced in the endothelium of high-grade human brain tumors. Inhibition of PV-1 expression is associated with failure of endothelial differentiation in vitro. PV-1 represents a novel marker of brain tumor angiogenesis and integrity of the blood-brain barrier and is a potential therapeutic target.
PURPOSE:Plasmalemmal vesicle associated protein-1 (PV-1) is up-regulated in the endothelium of humanglioblastoma. We sought to further characterize the expression pattern of PV-1 in humanbrain tumors and interrogate its role in brain tumor angiogenesis. EXPERIMENTAL DESIGN: Quantitative reverse transcription-PCR and in situ hybridization were used to measure PV-1 expression in a panel of 46 humanbrain tumors and related pathologic states. Matrigel tubulogenesis assays and cell migration assays were used to show function of PV-1 in primary human endothelial cells (HMVEC) under gene knockdown conditions. RESULTS:PV-1 is selectively up-regulated in a variety of high-grade humanbrain tumors, including glioblastoma and metastatic carcinoma, as well as other cerebral disorders associated with blood-brain barrier disruption, such as acute ischemia. Expression levels were reduced in low-grade neoplasia; however, tumors associated with the ependyma and choroid plexus, known sites of PV-1 expression, also exhibited robust expression. Cerebral expression of PV-1 mRNA was confined to endothelial cells in all cases. PV-1 expression was induced in HMVEC cells in vitro by exposure to medium conditioned by U87MG and U251MG humanbrain tumor cell lines and by medium supplemented with exogenous vascular endothelial growth factor or scatter factor/hepatocyte growth factor. RNA interference-mediated inhibition of PV-1 induction in HMVEC cells blocked Matrigel-induced tubulogenesis and inhibited cell migration induced by conditioned medium or angiogenic growth factors. CONCLUSIONS: Our results confirm that PV-1 is preferentially induced in the endothelium of high-grade humanbrain tumors. Inhibition of PV-1 expression is associated with failure of endothelial differentiation in vitro. PV-1 represents a novel marker of brain tumor angiogenesis and integrity of the blood-brain barrier and is a potential therapeutic target.
Authors: V P Chekhonin; V P Baklaushev; G M Yusubalieva; O I Gurina; T B Dmitrieva Journal: Dokl Biochem Biophys Date: 2008 Jan-Feb Impact factor: 0.788
Authors: Philippe Ciofi; Maurice Garret; Olivier Lapirot; Pierrette Lafon; Anne Loyens; Vincent Prévot; Jon E Levine Journal: Endocrinology Date: 2009-10-16 Impact factor: 4.736
Authors: Jiyong Zhang; Grazyna B Sadowska; Xiaodi Chen; Seon Yeong Park; Jeong-Eun Kim; Courtney A Bodge; Erin Cummings; Yow-Pin Lim; Oleksandr Makeyev; Walter G Besio; John Gaitanis; William A Banks; Barbara S Stonestreet Journal: FASEB J Date: 2015-01-21 Impact factor: 5.191
Authors: Robyn A Umans; Hannah E Henson; Fangzhou Mu; Chaithanyarani Parupalli; Bensheng Ju; Jennifer L Peters; Kevin A Lanham; Jessica S Plavicki; Michael R Taylor Journal: Dev Biol Date: 2017-03-29 Impact factor: 3.582
Authors: Radu V Stan; Dan Tse; Sophie J Deharvengt; Nicole C Smits; Yan Xu; Marcus R Luciano; Caitlin L McGarry; Maarten Buitendijk; Krishnamurthy V Nemani; Raul Elgueta; Takashi Kobayashi; Samantha L Shipman; Karen L Moodie; Charles P Daghlian; Patricia A Ernst; Hong-Kee Lee; Arief A Suriawinata; Alan R Schned; Daniel S Longnecker; Steven N Fiering; Randolph J Noelle; Barjor Gimi; Nicholas W Shworak; Catherine Carrière Journal: Dev Cell Date: 2012-12-11 Impact factor: 12.270
Authors: Nino Muradashvili; Richard L Benton; Kathryn E Saatman; Suresh C Tyagi; David Lominadze Journal: Metab Brain Dis Date: 2014-04-29 Impact factor: 3.584
Authors: Wei Qiu; Eleanor B Carson-Walter; Hongtao Liu; Michael Epperly; Joel S Greenberger; Gerard P Zambetti; Lin Zhang; Jian Yu Journal: Cell Stem Cell Date: 2008-06-05 Impact factor: 24.633
Authors: Eleanor B Carson-Walter; Bethany N Winans; Melissa C Whiteman; Yang Liu; Sally Jarvela; Hannu Haapasalo; Betty M Tyler; David L Huso; Mahlon D Johnson; Kevin A Walter Journal: BMC Cancer Date: 2009-11-30 Impact factor: 4.430